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Abstract
The world is suffering from a pandemic called COVID-19, caused by
the SARS-CoV-2 virus. National governments have problems evaluating
the reach of the epidemic, due to having limited resources and tests at
their disposal. This problem is especially acute in low and middle-income
countries (LMICs). Hence, any simple, cheap and flexible means of eval-
uating the incidence and evolution of the epidemic in a given country
with a reasonable level of accuracy is useful. In this paper, we propose
a technique based on (anonymous) surveys in which participants report
on the health status of their contacts. This indirect reporting technique,
known in the literature as network scale-up method, preserves the pri-
vacy of the participants and their contacts, and collects information from
a larger fraction of the population (as compared to individual surveys).
This technique has been deployed in the CoronaSurveys project, which
has been collecting reports for the COVID-19 pandemic for more than
two months. Results obtained by CoronaSurveys show the power and
flexibility of the approach, suggesting that it could be an inexpensive and
powerful tool for LMICs.
Keywords: Epidemics, surveys, network scale-up method, indirect reporting,
crowdsourcing, privacy.
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1 Introduction
During the current SARS-CoV-2 virus pandemic, monitoring the evolution of
COVID-19 cases is very important for authorities to make informed policy de-
cisions, and for the general public to be informed of the reach of the problem.
Official numbers of confirmed cases are periodically issued by health authorities
[4]. Unfortunately, at the early stages of a pandemic outbreak there is usually
only limited ability to test, as well as a lack of other resources. Hence, it is
not possible to test all potential cases, and some eligibility criteria is applied to
decide who is tested. Under these circumstances, the official confirmed cases are
unlikely to represent the total number of cases (see [10]). This problem is more
pressing in low and middle-income countries (LMICs), which may be limited in
their ability to deploy massive testing. Not having access to reliable data clearly
prevents authorities from making informed decisions, putting the population at
higher risk.
This motivates the need for other probing techniques, beyond laboratory
testing, that can estimate the number of cases and their evolution. Informa-
tion obtained using these alternative methods can be more timely, leaving more
accurate estimates of the number of cases for later studies (e.g., massive sero-
logical studies [16]). Techniques that allow cheap and massive data collection,
and lead to reasonably accurate estimates, are useful when testing is limited
and can lead to improved data-driven decision making.
Direct surveys are an obvious approach to estimate incidence. A number
of these direct surveys to obtain health data have been deployed in various
countries in recent months [8, 12, 5]. While these surveys can gather useful
data, a large number of participants is needed to achieve reliable estimates.
Additionally, these surveys collect sensitive personal health information, which
prevents the distribution of the raw data collected, and may also discourage
privacy-concerned people from responding.
In this paper, as an alternative to direct surveys, we propose surveys with
indirect reporting, where the questions a participant answers are not about her-
self, but about her contacts. This technique is known in the literature as the
network scale-up method [2, 1], and has been successfully used for public health.
This approach has at least two major advantages with respect to direct surveys.
First, the survey can be designed so that no personal information is collected
from the participant (i.e., it is completely anonymous). Second, indirect report-
ing has a multiplicative effect, since it reduces the number of responses required
to achieve a specific population coverage. The loss in accuracy, due to respon-
dents not always having exact information about the health status of others,
may be compensated by the significant increase in coverage (i.e., on average
each respondent informs about the likely status of around 100 other people).
We have designed and deployed a system that implements the network scale-
up method via anonymous surveys with indirect reporting, as part of the Coro-
naSurveys project [13]. This system has surveys in multiple languages and
allows reporting data on the incidence of COVID-19 in all countries. It has
been collecting data for more than 2 months now, and has collected more than
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13, 000 responses, reporting cases in 70 countries. All the collected data is avail-
able to be openly used1. In parallel with the data collection, the CoronaSurveys
project has been developing statistical techniques to estimate the incidence of
COVID-19 in different countries and geographical areas.
In the rest of this paper, we present the different elements of the CoronaSur-
vey project, and compare our resulting estimates with those obtained via other
indirect methods and a wide systematic serology study conducted in Spain [6].
Our estimates are surprisingly close to the values obtained in the serological
study. From this, we conclude that anonymous open indirect surveys, in com-
bination with our proposed statistical techniques, provide a cheap and flexible
option for monitoring epidemics, especially in countries with limited infrastruc-
ture.
2 Estimates via Anonymous Surveys with Indi-
rect Reporting
This section describes the two main components of the CoronaSurvey project:
collection of survey responses and estimation of COVID-19 incidence from the
collected responses.
2.1 Data Collection: The Survey
Our proposed surveys are carefully designed to avoid querying participants
about their own health status2, identity, or any personal data. In order to pro-
vide data for estimating incidence, participants answer three questions. First,
they select a geographical area, which can be a whole country or a region within
a country. (The participant does not need to be a resident of that area.) Then,
they answer two simple questions about that area:
• How many people do you know in this geographical area? (Please, consider
only people whose current health status you likely know.)
• As far as you know, how many of the above have had symptoms compatible
with COVID-19 (or were diagnosed with the disease)?
We aim at increasing participation by not asking for any personal informa-
tion (protecting the participant’s privacy), and by having just two questions3.
However, the lack of detailed information about the participants makes the esti-
mation process more challenging. In particular, we do not control the spread of
1https://github.com/GCGImdea/coronasurveys/tree/master/data
2While in general reporting on one’s own health status without any identifying information
would not have privacy implications, it could increase the risk for de-anonimization attacks if
the raw data is publicly shared, or the survey system is compromised.
3In the new version of the survey we have additional questions to estimate other aspects
of the epidemic, but the total number of questions we include remains very small (10 or less),
compared with most surveys (e.g., [5] has more than 30 questions).
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the survey and do not have means to ensure that there is an adequate coverage,
in terms of regions, age groups and other demographic factors.
The main novelty of our proposed survey is that a participant does not re-
port on her own health status but on those of others. This typically leads each
participant to report on the health status of a large sample (around one hundred
on average), which significantly increases our coverage of the population. We
believe that this is the reason why, somewhat surprisingly, even with the limita-
tions in the available data and few responses, we can still obtain estimates that
are less than 4% away from the real value (see Section 3.3). Obvious advantages
of this approach are that it is very simple to deploy and can give very timely
results.
We started the project by running discrete surveys in Spain and evolved the
system so that now it collects data continuously. We have been running the sur-
vey (starting with a simpler version) in some countries for more than 2 months
(since March 13). The survey is now available in 57 languages. Participants
can report at the regional level in 149 countries and at the country level in all
countries of the world. We have already collected more than 13, 000 responses
for 70 countries.
2.2 Computing Incidence Estimates
Country-wide and regional estimates We use responses to our survey to
estimate the incidence of COVID-19 in different countries. Respondents can
report on the number of people they know for a specific region or for the whole
country. Currently, when the data availability allows it, estimates for a given
country are computed based only on the regional responses, because country-
wide responses tend to introduce a geographical bias.
For instance, our initial estimates for Spain were ignoring regional informa-
tion, and considering all responses as referring to the whole country. However,
we observed that most of our responses were actually from the region of Madrid,
which is the most affected region in Spain, and thus tended to report high inci-
dence ratios. This was in line with the prevalence in Madrid, but not necessarily
a good reflection of country-wide conditions. We then computed new estimates
by taking regional information into account and confirmed that we were initially
over estimating the number of cases in Spain.
We also decided to use only the responses that specify a region as it is rea-
sonable to assume that country-wide responses will share a similar bias (com-
ing from the most affected region)4. Note that while we observed this bias in
one specific dataset (Spain), similar problems could arise in other countries.
COVID-19 outbreaks have been fairly localized in most countries, with different
prevalence observed at the region or state level. Thus, answers that provide
information within a region tend to lead to more reliable estimates in general.
We therefore plan to remove the country-wide option in future survey updates.
4This probably also results from the fact that we spread our survey through social connec-
tions starting from our researchers based in Madrid.
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COVID-19 incidence estimation – Region based approach Assume the
country of interest is divided into k regions. In each region i, we get ni responses,
where each response j contains:
• a reach variable, rji , which is the network size of participant j (i.e., the
number of people whose health she knows; answer to the first survey ques-
tion) and
• a count variable, cji , which is the number of people (out of the rji reached)
that are known to the respondent to be showing symptoms compatible
with COVID-19 (answer to the second survey question),
for j ∈ {1, . . . , ni}. Then, we obtain an estimate of the ratio of people infected
with symptoms in region i, pˆi, using [1]
pˆi =
∑ni
j=1 c
j
i∑ni
j=1 r
j
i
.
From the ratios pˆi of the different regions, we compute an estimate of the
proportion of those infected with symptoms in the country, pˆ, using a weighted
sum of these ratios as follows.
pˆ =
k∑
i=1
ωipˆi,
where ωi is a proportional weight defined as
ωi =
Ni
N
,
where Ni and N are the populations of region i and the whole country, respec-
tively. To build a confidence interval for pˆ, we need to estimate its variance
V (pˆ). To do so, we consider each region as a stratum in a post-stratified
random-sampling setting, and estimate the variance of proportions for post-
stratified sampling [7] as
V (pˆ) =
1− f
n
k∑
i=1
ωiS
2
i +
1− f
n2
k∑
i=1
(1− ωi)S2i ,
where n =
∑k
i ni and f = n/N . The value S
2
i for each region can be estimated
using
S2i =
ni∑
j=1
(pij − pˆi)2
ni − 1 ,
where pij =
cj
i
rj
i
. We can then construct a confidence interval for pˆ as
pˆ± 1.96
√
V (pˆ).
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Before generating an estimate for a given country at a given date, we first
clean the survey responses by identifying and removing outliers. We declare a
response to be an outlier if rji , the number of persons that the participant claims
to know, is unusually large (specifically, we remove entries where rji is beyond
1.5 times the interquartile range above the upper quartile). We also consider to
be outliers responses leading to a large ratio pij of symptomatic people reported
(specifically, we remove entries in which the ratio cji/r
j
i is above 0.3). We remove
responses with large ratios because we aim at surveying the general population,
and not individuals (such as doctors or nurses) who may be in contact with a
large number of symptomatic cases.
After outlier removal, for any given day we aggregate data from that day
and from previous days until we have at least Amin responses. For the experi-
ments we report here we set Amin = 300, as we observed empirically that this
provides enough data to make our estimate reliable. Since we usually do not
get Amin responses on a given day for most countries, using data from previous
days also provides a rolling estimate, which has an implicit smoothing effect
on the estimate. From these responses, we exclude country-wide responses (as
discussed earlier) and then compute the value of pˆi for each region i represented
in the responses. Then, the estimate of the proportion of people infected with
symptoms in the country, pˆ, for the day is computed as shown above.
The described procedure produces reasonable estimates and works well as
long as we have a sufficiently large number of responses (per day). Hence, we
have only applied this procedure to generate estimates from data gathered in
Spain, Portugal, and Ukraine, countries from which we got the highest number
of responses.
COVID-19 incidence estimation – Country based approach For coun-
tries where the number of survey responses is smaller (after removing outliers),
we have used a simpler estimation procedure. Denote nd the number of re-
sponses collected on day d for the given country (counting both regional and
country-wide responses after removing outliers). If nd ≥ amin, we estimate the
incidence of COVID-19 in the country of interest using
pˆd =
∑nd
l=1 cl∑nd
l=1 rl
,
where rl is the number of people a participant l declares to know in the first
question of the survey, and cl is the number of people (out of rl) showing symp-
toms compatible with COVID-19, for l ∈ {1, . . . , nd}. On the other hand, if
nd < amin, we do not compute an estimate for day d. We instead aggregate
the responses for day d to the responses for the subsequent days d+ 1, d+ 2, . . .
until we have a day d′ = d+m such that nm = nd + nd+1 + . . .+ nd+m ≥ amin
responses. In the experiments reported here we empirically chose amin = 30.
We then compute the estimate pˆd′ for day d
′ as5
5We expect that better results may be achievable if Amin and amin are selected as a function
of country population. We plan to investigate this in future work.
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pˆd′ =
∑nm
l=1 cl∑nm
l=1 rl
.
The estimates pˆd and pˆd′ are simple proportions and we construct a 95%
confidence interval for pˆ ∈ {pˆd, pˆdm} using confidence intervals for binomial
proportions as follows
pˆ± 1.96
√
pˆ(1− pˆ)
r
,
where r =
∑
l rl. A major limitation of this method is that we do not obtain
estimates for every day. However, we are constantly refining these techniques,
and trying new ways to obtain better estimates.
3 Validation
In the previous sections we introduced our strategy for indirect reporting of the
number of cases. Given the nature of an open and anonymous survey, where data
quality is much harder to enforce, we soon identified the need for an independent
estimator to which we could compare the survey results. In most countries we
had access to time series with the number of official, RT-PCR confirmed, cases
and COVID-19 mortality data. Together these series allow the derivation of a
naive case fatality ratio (CFR).
Up to early May 2020 our running option for an independent estimator was
to use the CFR to estimate the current number of cases in each country, as
detailed in the next section. On May 13, 2020, a large-scale serology study was
reported for Spain [6] and this provided a more precise and direct data collection
for calibration.
3.1 Inferring Cases from Reported Mortality
In an ongoing epidemic, the current CFR should be calculated by taking into
account the number of deaths over the number of current cases with known
outcomes, since very recent cases can still evolve as fatalities or recovery [11].
This correction yields a corrected CFR (cCFR), more accurate than the naive
CFR that is often reported.
Under the assumption that the disease has similar mortality rates for similar
populations, it is possible to use stable cCFR estimates to obtain a baseline,
cCFRb, for COVID-19 and check how each country’s current cCFR compares
to that baseline, and hence infer the proportion of cases that are being detected
[14]. If we multiply the reported number of cases by cCFRcCFRb
, we obtain an
estimate for the likely true number of cases in that given country.
In [15] the authors report, from a large sample of cases in China, a base-
line cCFRb of 1.38%. We currently use this baseline. Still, given that several
countries (North Korea, New Zealand, and others) have stabilized the growth of
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COVID-19 cases, it is possible to use the data in those countries to also define
a baseline.
We observe that one limitation of resorting to reported mortality data is that
some countries might not properly report or classify it as COVID-19 mortality.
However, in countries with adequate reporting, it is a useful source of calibration
and independent estimation.
3.2 Serology Study in Spain
On May 13, 2020 the Spanish Government published a first report from a large-
scale serology study that looked for COVID-19 antibodies in the population [6].
Samples were collected from April 27 to May 11, and results made available from
a group of 60, 897 participants in the study, selected according to demographic
criteria, to obtain a representative sample of the population. Although both
IgM and IgG antibodies were measured, the report focuses on the prevalence of
SARS-Cov2 IgG antibodies. The overall prevalence was reported as 5.0% (95%
CI: 4.7%-5.4%), and regional variations ranged from 1.1% in Ceuta to 11.3% in
the Comunidad de Madrid.
The IgG test was found to have a sensitivity of 79% and specificity of 100%.
Given that, we can correct for false negatives and estimate an overall infection
rate of 6.33% (=0.05/0.79). Assuming an average time span of two weeks since
infection to the development of detectable levels of IgG [9], and with a popula-
tion in Spain of 46, 934, 628 persons, this leads to an estimate of approximately
2, 970, 546 cumulative cases around the weeks from April 13 to 27 (in the mid-
dle of this period, on April 20, the number of RT-PCR confirmed cases was
200, 210, almost 15 times lower). Using the cumulative mortality on May 11
(roughly two weeks after the likely infection dates) of 26, 744, this leads to an
estimated infection mortality rate (IFR) of around 0.9%.
The study includes data on the proportions of IgG positives that had one
or more symptoms or were completely asymptomatic. The proportion of IgG
positives with some kind of symptoms (i.e. at least one symptom) is 66.27%.
With this, one can estimate about 1, 968, 550 persons with symptoms, and a
CFR of around 1.36% (actually very close to the value calculated for Wuhan at
1.38% [15]).
3.3 Comparing Estimates
Adopting as ground truth the serology-derived value of 6.33% cumulative infec-
tions in the period from April 13 to 27 (which lead to 79% IgG positives two
weeks later, i.e. 5%), we compare this ground-truth to our estimates in the same
period. Since our estimates, cCFR-based and survey-based, target symptomatic
cases, we need to scale them to total infections by dividing the estimates by 0.66
(the ratio of symptomatic over total infections as reported in the study [6]). We
also show, for comparison, the number of reported RT-PCR confirmed cases.
As we can see in Figure 1 the official RT-PCR data is about an order of
magnitude less than the likely true rate of infected people that is inferred from
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Figure 1: Case estimates for Spain, April 13 to 27, 2020.
IgG prevalence, 6.33%. Figure 1 also shows that both the cCFR-based estimate
and the estimate derived from the open survey closely track the IgG-prevalence
value. The average of the cCFR estimates in the 15-day period was 6.56%, while
that of the survey-based estimates was 6.2%. This places them, respectively,
only 0.24% and 0.13% apart from the IgG reference value (average relative
difference of 3.72% and 2.05%, respectively). These results show that open
surveys can bring relevant data on the size of a pandemic, which can be be useful
when more reliable metrics are not yet available or better estimates cannot be
implemented in some regions.
For further evaluation of our method we compare our estimates to the serol-
ogy data for each region in Spain as shown in Figure 2. We plot the relative
error in our estimate for a region as a function of the relative coverage of our
surveys for that region (reach divided by population). Although we can see
some variability, we note that the trend is towards lower relative error as the
reach increases.
4 Experience Using Open Surveys in LMI Coun-
tries
We have obtained estimates for a number of countries. In particular, we have
received enough responses to estimate symptomatic cases in 3 LMICs, namely
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Figure 2: Relative accuracy vs. local coverage: For each region, we plot the
relative error in our estimates as compared to serology data, shown as a function
of the relative reach within the region. Higher reach (better coverage within a
region) tends to lead to lower error.
Country Resp. Date Cases cCFR CoronaSurveys
% pop. % pop. (CI 95%) % pop. (CI 95%)
Brazil 41 May 17 0.11% 1.01% (1.00 - 1.01) 1.00% (0.56 - 1.43)
Ecuador 30 April 15 0.04% 0.31% (0.31 - 0.31) 1.61% (1.11 - 2.10)
Ukraine 30 April 26 0.02% 0.07% (0.07 - 0.07) 0.56% (0.25 - 0.88)
Table 1: Summary of estimates for Brazil, Ecuador and Ukraine in percentage
of the country population. Cases correspond to the official cumultive data on
that day, while cCFT and CoronaSurveys are estimates.
Brazil, Ecuador, and Ukraine (see Table 1).
In Brazil we have recent estimates for May 17, when the official number of
cumulative confirmed cases was 233, 142, and the official number of cumulative
fatalities was 15, 633. For that same date, the estimate based on the cCFR
is 2, 139, 681 (CI 95%: 2, 135, 408 - 2, 143, 963), 1.01% of the population, and
the estimate based on 41 survey responses is 2, 120, 134 (CI 95%: 1, 195, 676
- 3, 044, 593), 1% of the population. Not surprisingly, the estimated number
of cases is one order of magnitude larger than the number of confirmed cases.
However, it is remarkable how close the cCFR and survey-based estimates are
to each other, differing in less than 20, 000 cases (0.01% of the population).
In Ecuador we also observe that the number of estimated cases is at least one
10
order of magnitude larger than the official number of confirmed cases. However,
we observe that the estimates from cCFR and from the surveys are also very
different. For instance, we have estimates dated April 15, when the official
number of confirmed cases was 7, 603 and the official number of fatalities was
355. Our case estimate for that date from the cCFR is 53, 435 (CI 53069 -
53804), 0.31% of the population, and the one from 30 survey responses is 274, 668
(CI 190, 236 - 359, 100), 1.61% of the population. We observe a significant
difference between the two estimates, the one from the surveys being 5 times
larger than the cCFR-based one. This difference does not seem to be the result
of geographical bias, since few survey responses came from the provinces with
the largest number of cases (e.g., Guayas).
We observed a similar behavior in Ukraine where, again, the estimates are
at least one order of magnitude larger than the number of confirmed cases, and
the number of estimated cases from the surveys is one order of magnitude larger
than the estimates from cCFR. For instance, the latest direct estimate from (30)
survey responses was done on April 26, and has a value of 246, 646 (CI 107, 482
- 385, 811), 0.56% of the population, while the cCFR estimate is 32, 078 (CI
31, 734 - 32, 426), 0.07% of the population. The confirmed numbers of cases and
fatalities on that date were 8, 617 and 209, respectively. This result is not due
to a geographical bias, since the region-based estimate for that same day from
300 survey responses is 159, 529 (CI 62, 361 - 256, 696), 0.35% of the population,
which is lower, but still five times higher than the cCFR-based estimate.
The results in Ecuador and Ukraine are puzzling, and we are not able to
explain them yet. Our current hypothesis is that these countries use different
criteria for reporting cases and fatalities than the countries we use as reference.
This may cause the cCFR-based estimate to be unreliable. We have deployed
additional questions in the survey that we believe can be used to track the
difference. The good news is that this can be done with very little effort, and
we do not need a lot of responses to have enough information to have solid
conjectures.
5 Discussion
By now it is clear that relying only on confirmed cases and fatalities to measure
the true size of a growing pandemic is not a good idea. It is possible to use
this data to derive estimates, like the one we obtain here based on the cCFR,
that are reasonably reliable in countries with a good reporting system. This has
been shown in the case of Spain using the ground truth provided by a serological
study. The same study indicates that open anonymous surveys with indirect
reporting also provide estimates that are close to the real values. The match-
ing between cCFR-based and survey-based estimates has also been observed in
Brazil. However, we have found countries in which there is no ground truth, and
the cCFR-based and survey-based estimates differ significantly. We are inves-
tigating this further by adding new questions to the surveys in these countries,
which will provide additional information on the causes of these discrepancies.
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We are aware that having open anonymous surveys prevents a tight control
of the population of participants. Hence, our responses may be suffering of
strong biases: for example, they may be close geographically and socially to the
team members, which are the ones promoting the survey. We are also aware
that the set of people and cases participants report are possibly not disjoint.
Interestingly, until now the only bias that we have observed to be relevant is
the geographical bias. The intersection of contacts among participants does not
seem to have much influence on the estimates. However, we plan to explore
ways to influence the population of participants. One line to follow is the use
of targeted campaigns in social networks and web ads (using Facebook Ads or
Google Ads), in which we have control over who sees a given ad promoting the
survey. This will allow targeting participants from certain geographical areas
and certain demographic profiles.
While we only present here tecniques for obtaining estimates on the number
of people infected with COVID-19, we are designing new surveys that will hope-
fully allow us to estimate other important parameters of the pandemic, like the
number of newly infected cases, the reproduction number, or the forecast needs
of health equipment and infrastructures.
We believe that a survey system like the CoronaSurveys project is especially
suited for LMICs, since the cost of preparing and deploying a survey is extremely
small, participants can use very simple devices to fill the survey (since it is web
based), and the number of participants required to have information on the
pandemic is rather low. Having a uniform approach to obtain this information
in many countries also makes the process especially interesting, since it avoids
the current problems with different ways of counting and measuring.
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